Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Sankyo Co., Ltd.
  6. Summary
    6417   JP3326410002

SANKYO CO., LTD.

(6417)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Japan Exchange
01/21/2022 01/24/2022 01/25/2022 01/26/2022 01/27/2022 Date
3025(c) 3050(c) 2973(c) 2983(c) 2928(c) Last
188 800 152 900 396 500 314 100 377 200 Volume
+0.83% +0.83% -2.52% +0.34% -1.84% Change
More quotes
Estimated financial data (e)
Sales 2022 80 831 M 703 M 703 M
Net income 2022 10 020 M 87,1 M 87,1 M
Net Debt 2022 - - -
P/E ratio 2022 17,7x
Yield 2022 3,35%
Sales 2023 79 300 M 690 M 690 M
Net income 2023 8 813 M 76,6 M 76,6 M
Net Debt 2023 - - -
P/E ratio 2023 20,2x
Yield 2023 3,35%
Capitalization 178 B 1 558 M 1 549 M
Capi. / Sales 2022 2,20x
Capi. / Sales 2023 2,25x
Nbr of Employees 964
Free-Float 57,2%
More Financials
Company
Sankyo Co Ltd is a Japan-based company mainly engaged in the pachinko machine related business, pachislot machine related business, and replenishment equipment related business. The Company operates through three business segments. The Pachinko Machine-related Business segment is engaged in the manufacture and sale of pachinko machines and gauge boards for pachinko machines, the sale of related parts, and... 
Sector
Casinos & Gaming
Calendar
02/10Earnings Release
More about the company
Ratings of Sankyo Co., Ltd.
Trading Rating :  -
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about SANKYO CO., LTD.
01/18FDA Grants Priority Review to AstraZeneca's Enhertu for Treatment of HER2-Positive Meta..
MT
01/17AstraZeneca's Enhertu Granted Priority Review by US Regulator
DJ
01/17AstraZeneca-Daiichi Sankyo's Breast Cancer Drug Accepted For Priority Review in US
MT
01/05Tranche Update on Sankyo Co., Ltd.'s Equity Buyback Plan announced on November 8, 2021.
CI
01/04Japanese shares edge higher as gains in Toyota, Sony offset tech losses
RE
2021AstraZeneca, Daiichi Sankyo's Trastuzumab Deruxtecan Gets EMA Validation For Breast Can..
MT
2021AstraZeneca's Partner Doses First Patient in Late-Stage Trial of Enhertu in Patients Wi..
MT
2021Nikkei ends 2% higher on bargain-buying, led by tech shares
RE
2021Japanese shares jump on bargain hunting, chip sector shines
RE
2021Gilead Sciences Unit, Daiichi Sankyo Launch Cell Therapy Product in Japan
MT
2021Sankyo Eyes Prime Market Listing
MT
2021SANKYO : Notice concerning Application for Selection of Prime Market in New Market Segment..
PU
2021AstraZeneca-Daiichi Sankyo's Enhertu Improves Progression-Free Survival, Objective Resp..
MT
2021AstraZeneca's Drug Candidate Shows Durable Tumor Response in Triple Negative Breast Can..
MT
2021Nikkei 225 Down 0.4% on Omicron Variant Concerns
MT
More news
News in other languages on SANKYO CO., LTD.
01/17ASTRAZENECA : obtient l'examen prioritaire pour Enhertu
01/17Le médicament contre le cancer du sein d'AstraZeneca-Daiichi Sankyo a été accepté pour ..
2021Le Trastuzumab Deruxtecan d'AstraZeneca et Daiichi Sankyo est validé par l'EMA pour le ..
2021Le partenaire d'AstraZeneca administre la dose au premier patient d'un essai de stade a..
2021Vifor Pharma trouve un accord avec des fabricants de génériques
More news
Chart SANKYO CO., LTD.
Duration : Period :
Sankyo Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANKYO CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Last Close Price 2 983,00 JPY
Average target price 3 550,00 JPY
Spread / Average Target 19,0%
EPS Revisions
Managers and Directors
Hideyuki Busujima President & Representative Director
Akihiko Ishihara President, COO & Representative Director
Yoko Oshima GM-Administration & Manager-General Affairs
Taro Kitani Independent Outside Director
Hiroyuki Yamasaki Independent Director
Sector and Competitors